Autoimmune myasthenia gravis

Expert Review of Neurotherapeutics

Volumn 9, Issue 3, 2009, Pages 351-358

  Gilhus, Nils Erik ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acetylcholine receptor antibodies; Anti MuSK antibodies; Immunosuppressive therapy; Myasthenia gravis; Thymoma; Thymus

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISOLONE; PYRIDOSTIGMINE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ANTIGEN PRESENTATION; ARTIFICIAL VENTILATION; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOXICITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MYASTHENIA GRAVIS; NEPHROTOXICITY; NEUROIMAGING; NEUROIMMUNOLOGY; NEUROPHARMACOLOGY; NEUROPHYSIOLOGY; PATHOGENESIS; PLASMAPHERESIS; QUALITY OF LIFE; REVIEW; THYMECTOMY; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; EXPERT WITNESS; IMMUNOLOGY; METHODOLOGY;

CHOLINESTERASE INHIBITORS; EXPERT TESTIMONY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; THYMECTOMY;

EID: 66449124520     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.3.351     Document Type: Review

References (40)

1. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18, 519-525 (2005).
2. Leite MI, Jacob S, Viegas S et al. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 131, 1940-1952 (2008).
3. Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur. J. Neurol. 14, 617-620 (2007).
4. Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr. Opin. Neurol. 21, 8-15 (2008).
5. Skeie GO, Apostolski S, Evoli A et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 31, 691-699 (2006).
6. Skeie GO, Aarli JA, Gilhus NE. Thin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol. Scand. 113(Suppl. 183), 19-23 (2006).
7. Evoli A, Bianchi MR, Riso R et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann. NY Acad. Sci. 1132, 76-83 (2008).
8. Chavis PS, Stickler DE, Walker A. Immunosuppressive or surgical treatment for ocular myasthenia gravis. Arch. Neurol. 64, 1792-1794 (2007).
9. Gilbert ME, De Sousa EA, Savino PJ. Ocular myasthenia gravis treatement. Arch. Neurol. 64, 1790-1792 (2007).
10. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29, 484-505 (2004).
11. Barohn RJ. Treatment and clinical research in myasthenia gravis: how far have we come? Ann. NY Acad. Sci. 1131, 225-232 (2008).
12. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 371, 141-149 (2008).
13. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nauret. Clin. Pract. 4, 317-327 (2008).
14. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50, 1778-1783 (1998).
15. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. NY Acad. Sci. 681, 539-551 (1993).
16. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann. NY Acad. Sci. 1132, 305-314 (2008).
17. Sanders DB, Siddiqi ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann. NY Acad. Sci. 1132, 249-253 (2008).
18. Ponseti JM, Gamez J, Azem J, lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann. NY Acad. Sci. 1132, 254-263 (2008).
19. Newsom-Davis J, Cutter G, Wolfe GI et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann. NY Acad. Sci. 1132, 344-347 (2008).
20. Gronseth GS, Barohn RJ. Thymectomy for autoimmune myasthenia gravis: an evidence-based review. Neurology 55, 7-15 (2000).
21. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol. Scand. 111, 134-141 (2005).
22. Mantegazza R Baggi F, Bernasconi P et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients; remission after 6-years follow-up. J. Neurol. Sci. 212, 31-36 (2003).
23. Kondo K. Optimal therapy for thymoma. J. Med. Invest. 55, 17-28 (2008).
24. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia in pregnancy and birth; identifying risk factors, optimizing care. Eur. J. Neurol. 14, 38-43 (2007).
25. Hoff JM, Daltveit AK, Gilhus NE. Arthrogryposis multiplex congenital: a rare fetal condition caused by maternal myasthenia gravis. Acta Neurol. Scand. 113(Suppl. 183), 26-27 (2006).
26. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol. 41, 789-796 (1997).
27. Elovaara I, Apostolski S, van Doom P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15, 893-908 (2008).
28. Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J. Neurol. Neurosurg. Psychiat. 77, 203-207 (2006).
29. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann. NY Acad. Sci. 1132, 180-192 (2008).
30. Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152, 112-120 (2004).
31. Faria AMC, Weiner HL. Oral tolerance. Immunol. Rev. 206, 232-259 (2005).
32. Fostieri E, Kostelidou K, Poulas K, Tzartos SJ. Recent advances in the understanding and therapy of myasthenia gravis. Future Neurol. 1, 799-817 (2006).
33. Lindstrom J, Luo J, Kuryatov A. Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. Ann. NY Acad. Sci. 1132, 29-41 (2008).
34. Meriggioli MN, Sheng JR, Li L, Prabhakar BS. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann. NY Acad. Sci. 1132, 276-282 (2008).
35. Matsumoto Y, Matsuo H, Sakuma H et al. CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. J. Immunol. 176, 5100-5107 (2006).
36. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748-755 (2008).
37. Tzartos SJ, Bitzopoulou K, Gavra I et al. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann. NY Acad. Sci. 1132, 291-299 (2008).
38. Losen M, Martinez-Martinez P, Phernambucq M, Schuurman J, Parren PWHI, De Baets MH. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann. NY Acad. Sci. 1132, 174-179 (2008).
39. Sussman JD, Argov Z, McKee D, Hazum E, Brawer S, Soreq H. Antisense treatment for myasthenia gravis: experience with monarsen. Ann. NY Acad. Sci. 1132, 283-290 (2008).
40. Aricha R, Feferman T, Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB. J. 20, 374-376 (2005).